What is Adagene?
Adagene Inc. operates at the intersection of advanced immunology and oncology, specializing in the research, development, and production of monoclonal antibody drugs. The company distinguishes itself through its unique technology platforms, which are designed to engineer antibodies with high specificity and efficacy. By focusing on complex cancer pathways, Adagene has established a formidable market position, effectively bridging the gap between laboratory innovation and clinical application. Its operational model is characterized by a commitment to scientific rigor and a strategic focus on high-growth therapeutic areas, making it a focal point for investors seeking exposure to the evolving biopharmaceutical sector.
How much funding has Adagene raised?
Adagene has raised a total of $320M across 6 funding rounds:
Series A
$8M
Series B
$28M
Series C
$50M
Series D
$69M
Stock Offering
$140M
Other Financing Round
$25M
Series A (2014): $8M with participation from Fidelity Biosciences, Fidelity Asia Growth, and WuXi Venture Fund
Series B (2016): $28M led by Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), WuXi Corporate Venture Fund, New World TMT, GP Healthcare Capital, and F-Prime Capital (formerly Fidelity Biosciences)
Series C (2018): $50M supported by Sequoia China, New World TMT, Gopher Asset Management, King Star Capital, and AVIC Trust
Series D (2020): $69M featuring General Atlantic
Stock Issuance/Offering (2021): $140M, investors not publicly disclosed
Other Financing Round (2025): $25M with participation from Sanofi
Key Investors in Adagene
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on medicines and vaccines across immunology, oncology, and rare diseases.
Sequoia China
Sequoia China is a premier venture capital firm that partners with entrepreneurs to build enduring companies, leveraging a global network and deep expertise in the technology and healthcare sectors.
General Atlantic
General Atlantic is a global growth equity firm providing capital and strategic support to high-growth companies, with a strong emphasis on healthcare, life sciences, and technology transformation.
What's next for Adagene?
With the infusion of this recent capital, Adagene is well-positioned to accelerate its clinical development milestones and expand its research capabilities. The strategic nature of this funding suggests a focus on deepening partnerships and potentially scaling its manufacturing infrastructure to support late-stage trials. As the company navigates the complexities of the global regulatory environment, the emphasis will likely remain on validating its lead candidates and exploring potential licensing opportunities. Investors will be closely monitoring the firm's ability to translate its technological advantages into tangible clinical outcomes, which will be pivotal for its long-term valuation and market leadership in the oncology space.
See full Adagene company page
